Primary chemoresistance to the induction therapy of several AML patients assigned to the favorable risk category (Tables S7 and S9) may indicate an insufficient predictive value of the risk stratification by genetics, whereas the distribution of the patients into risk groups, considering the indicators of MDR phenotype such as sensitivity to chemotherapeutic drugs and MDR1 mRNA/P-gp expression in their tumor cells, demonstrated a stronger correlation with response to therapy and the survival of leukemia patients (Table 5, Table 6, Table 7, Figure 2). This evidence concerns the gene ABCB1 and neoplasm.